Kalaris Therapeutics (Nasdaq: KLRS), a clinical-stage biopharma focused on retinal diseases, will present Phase 1a single ascending dose data for lead asset TH103 in treatment-naïve neovascular age-related macular degeneration at Clinical Trials at the Summit 2026 in Las Vegas.
The session occurs June 13, 2026, 07:09 am PDT, in the Azure Ballroom.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – KLRS
-0.69%
1 alert
-0.69%Session close to close
$111.35MMarket Cap
0.0xRel. Volume
In the Jun 12 session, KLRS declined 0.69%, reflecting a mild negative market reaction.
This announcement spotlights additional visibility for TH103 Phase 1a data at CTS 2026, reinforcing ...
Analysis
This announcement spotlights additional visibility for TH103 Phase 1a data at CTS 2026, reinforcing Kalaris’s focus on neovascular AMD. Recent history shows multiple TH103 presentations and a strengthened balance sheet, alongside an effective $350,000,000 shelf that includes a $100,000,000 ATM program. Investors may watch for later-stage trial updates, financing usage under the shelf, and further clarity on development timelines.
Key Figures
Shelf registration:$350,000,000ATM program size:$100,000,000Director option grant:9,000 shares+5 more
8 metrics
Shelf registration$350,000,000Maximum securities registered on S-3 shelf
ATM program size$100,000,000At-the-market common stock sales agreement capacity
Director option grant9,000 sharesPer-director stock option grants reported on June 4, 2026
Option exercise price$4.72Exercise price for multiple director option grants
Controlling stake12,900,583 shares (54.2%)Reported beneficial ownership tied to Samsara BioCapital
Shares outstanding23,792,278 sharesOutstanding common stock as of May 5, 2026
Insider share purchase244,300 shares at $4.83Private purchase totaling $1,179,969 on May 20, 2026
Short interest3.76% of floatReported short position in KLRS shares
Positive initial Phase 1a TH103 nAMD data with functional and anatomic gains.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Positive clinical and earnings updates have produced mixed reactions, with several upbeat TH103 milestones followed by flat or negative next-day moves.
Recent Company History
Over the past six months, KLRS has focused on advancing TH103 and strengthening its balance sheet. Positive Phase 1a nAMD data and an oversubscribed $50.0M private placement in Dec 2025 were followed by full-year 2025 and Q1 2026 updates highlighting cash runway into Q4 2027. Prior presentations of TH103 Phase 1 data in early 2026 saw modest or negative price reactions, so today’s conference-focused announcement follows a pattern of clinically oriented catalysts driving stock-specific interest.
Key Terms
phase 1a, neovascular age-related macular degeneration, vegf, hspg, +2 more
6 terms
phase 1amedical
"will present Phase 1a clinical data for its lead asset, TH103"
Phase 1a is the initial part of a human clinical trial where a new drug or therapy is given to a small group of people for the first time to check safety, how the body handles it, and to identify appropriate dosing. Investors watch phase 1a like a vehicle's first test drive: clear safety and predictable behavior reduce risk and unlock value by allowing larger, more expensive trials to proceed and by increasing the chance of regulatory progress.
"treatment-naïve patients with Neovascular Age-Related Macular Degeneration (AMD)"
A progressive eye disease in older adults where abnormal blood vessels grow beneath the central retina and leak fluid or blood, quickly damaging sharp central vision used for reading and recognizing faces. For investors, it matters because it creates ongoing demand for medical treatments, diagnostics and follow-up care, and outcomes hinge on clinical trial results, regulatory approvals and reimbursement decisions that can sharply affect the value of companies developing therapies — like a chronic market need driven by a high-impact illness.
vegfmedical
"A Novel Dual-Targeting VEGF/HSPG Biologic in Treatment-Naïve nAMD"
Vascular endothelial growth factor (VEGF) is a naturally occurring protein that signals the body to grow new blood vessels, like a fertilizer prompts plants to sprout. It matters to investors because drugs that block or mimic VEGF can dramatically change outcomes for cancers and eye diseases, making them major drivers of clinical trial results, regulatory approvals, market value and future revenue potential for biopharma companies.
hspgmedical
"A Novel Dual-Targeting VEGF/HSPG Biologic in Treatment-Naïve nAMD"
Heparan sulfate proteoglycans (HSPGs) are large molecules found on cell surfaces and in connective tissue that act like molecular Velcro, helping cells stick together, communicate, and control the movement of signaling molecules. Investors track HSPGs because they play a role in disease processes and drug targeting—changes or therapies that affect HSPGs can alter how a treatment works, influence clinical trial outcomes, and affect the commercial prospects of biotech and pharmaceutical investments.
biologicmedical
"TH103: A Novel Dual-Targeting VEGF/HSPG Biologic in Treatment-Naïve nAMD"
A biologic is a medicine made from living cells or organisms—such as proteins, antibodies or vaccines—rather than being chemically synthesized. Investors watch biologics closely because they are expensive and complex to develop and manufacture, often enjoy strong market pricing and protections, and face unique regulatory and supply risks; think of them like handcrafted specialty goods versus mass-produced items with higher potential reward and higher production risk.
treatment-naïvemedical
"single ascending dose results from treatment-naïve patients with Neovascular"
Patients described as treatment-naïve have not previously received the therapy being studied or other prior treatments for the same condition, so their bodies are ‘untouched’ by those drugs. For investors, this matters because results in a treatment-naïve group show how a therapy performs without prior drug effects, influence trial design and regulatory labeling, and help estimate the size and profile of the initial market—like testing a new seed in a garden that has never been treated before.
BERKELEY HEIGHTS, N.J., June 12, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, will present Phase 1a clinical data for its lead asset, TH103, at Clinical Trials at the Summit (CTS) 2026. The presentation will feature single ascending dose results from treatment-naïve patients with Neovascular Age-Related Macular Degeneration (AMD) — one of the leading causes of vision loss worldwide. These data were recently presented at Retina World Congress 2026.
Details:
Title: First-in-Human Trial of TH103: A Novel Dual-Targeting VEGF/HSPG Biologic in Treatment-Naïve nAMD
Speaker: Karl Csaky, MD, PhD, T. Boone Pickens Director, Molecular Ophthalmology Laboratory; Director, Clinical Center of Innovation for AMD; Chief Strategy Officer, Retina Foundation of the Southwest
Date: Saturday, June 13, 2026
Time: 07:09 am PDT
Session: Clinical Trials Investigating Therapies with Novel Mechanisms of Action
Location: Azure Ballroom, Fontainebleau Hotel, Las Vegas, NV
AboutTH103
TH103 is an investigational dual-targeting biologic engineered by VEGF scientific discoverer Dr. Napoleone Ferrara to achieve extended intraocular retention with enhanced VEGF inhibition through optimized binding to VEGF receptor 1 ligands and concurrent heparan sulfate proteoglycan (HSPG) anchoring. It is a fully humanized, recombinant fusion protein designed for intravitreal delivery, with potential applications as a treatment for exudative and/or neovascular retinal diseases, such as wet AMD, diabetic eye disease and retinal vein occlusion. TH103 is currently being investigated in a Phase 1b/2 clinical trial in patients with neovascular Age-related Macular Degeneration (nAMD).
AboutKalaris
Kalaris Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases. Founded by renowned scientist Dr. Napoleone Ferrara, whose pioneering research led to the development of anti-VEGF therapy, the company is committed to advancing novel therapeutic approaches for patients with sight-threatening retinal conditions with major unmet medical needs.
What will Kalaris Therapeutics (NASDAQ: KLRS) present about TH103 at CTS 2026?
Kalaris will present Phase 1a single ascending dose data for TH103 in neovascular AMD. According to Kalaris, these first-in-human results evaluate a novel dual-targeting VEGF/HSPG biologic in treatment-naïve patients at Clinical Trials at the Summit 2026.
When and where is the Kalaris (KLRS) TH103 presentation at Clinical Trials at the Summit 2026?
The TH103 presentation is scheduled for Saturday, June 13, 2026, at 07:09 am PDT. According to Kalaris, it will take place in the Azure Ballroom at the Fontainebleau Hotel, Las Vegas, during a session on novel mechanisms of action.
Who is presenting Kalaris Therapeutics’ TH103 Phase 1a data at CTS 2026?
Karl Csaky, MD, PhD, will present the TH103 Phase 1a data. According to Kalaris, he serves as T. Boone Pickens Director, Molecular Ophthalmology Laboratory, Director, Clinical Center of Innovation for AMD, and Chief Strategy Officer at Retina Foundation of the Southwest.
What disease area does Kalaris’ lead asset TH103 target in the CTS 2026 presentation?
TH103 targets neovascular age-related macular degeneration (nAMD) in treatment-naïve patients. According to Kalaris, nAMD is a prevalent retinal disease and a leading cause of vision loss worldwide, making these first-in-human Phase 1a data clinically relevant.
Are the TH103 Phase 1a data at CTS 2026 new for Kalaris Therapeutics (KLRS)?
The TH103 Phase 1a data are being re-presented at CTS 2026 after Retina World Congress 2026. According to Kalaris, the CTS session highlights single ascending dose results in treatment-naïve neovascular AMD patients using a dual-targeting VEGF/HSPG biologic.
